SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.27-0.7%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (405)9/29/1999 11:22:00 PM
From: Bob L   of 52153
 
When Lehman Bros downgraded CLTR last month, they reduced their bexxar sales estimates for 2000, 2001 and 2002 to $66 million, $137 million, and $182 million, respectively. Substantially less than the $254 they previously estimated for 2002, but still a fair piece of change compared to current capitalization. This estimate included an assumption of larger sales for Zevalin than previously expected. As Peter suggests, this is now the big issue.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News